Abstract: Objective To studythe effect and prognosis of 35 cases of trigeminal neuralgia treated by percutaneous semilunar ganglion balloon compression.
Methods 70 patients of trigeminal neuralgia who received therapy from June 2018 to June 2019 in our hospital were selected,they were divided into the treatment group and the control group by the random number table,35 cases in each group.The control group was treated with carbamazepine,continuous medication for 1 month,while the treatment group was treated with percutaneous transluminal balloon compression.The clinical effect,the change of visual analogue scale(VAS) and the recurrence rate within 1 year were compared between the two groups,and the safety of treatment was evaluated.
Results After treatment of 1 month,the total effective rate of pain relief in the treatment group was 97.14%,which was significantly higher than that in the control group 80.00%(P＜0.05);the VAS scores of the treatment group at after treatment 1,2 and 4 weeks were significantly lower than that in the control group(P＜0.05);in the two groups of cured patients,the recurrence rate in the treatment group at 6 and 12 months was were significantly lower than that in the control group,and the VAS score at 12 months recurrence was significantly lower than that in the control group(P＜0.05);the main complications of the treatment group were numbness of the operation side,weakness of masticatory muscles and herpes of the mouth,the main adverse reactions of the control group were dizziness,nausea,vomiting and drowsiness.
Conclusion Percutaneous transluminal balloon compression is well for trigeminal neuralgia,which can effectively relieve the pain symptoms,reduce the recurrence rate and improve the prognosis.

Key words: trigeminal neuralgia, percutaneous transluminal balloon compression, carbamazepine, recurrence rate, safety